Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05300048
Title Combination of Serabelisib and Insulin Suppressing Diet in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Faeth Therapeutics
Indications

endometrial adenocarcinoma

endometrial serous adenocarcinoma

endometrial carcinoma

ovarian clear cell carcinoma

rectum adenocarcinoma

endometrial squamous cell carcinoma

colon adenocarcinoma

Advanced Solid Tumor

uterine carcinosarcoma

endometrioid ovary carcinoma

endometrial transitional cell carcinoma

endometrial clear cell adenocarcinoma

Therapies

Serabelisib

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama Recruiting Birmingham Alabama 35429 United States Details
Pacific Cancer Specialists Recruiting Anaheim California 92801 United States Details
Hoag Memorial Hospital Presbyterian Recruiting Newport Beach California 92663 United States Details
University of Chicago Not yet recruiting Chicago Illinois 60637 United States Details
Mayo Clinic - Rochester Not yet recruiting Rochester Minnesota 55902 United States Details
Memorial Sloan Kettering Cancer Center Not yet recruiting New York New York 10065 United States Details
East Carolina University Not yet recruiting Greenville North Carolina 27858 United States Details
Avera Cancer Institute Recruiting Sioux Falls South Dakota 57105 United States Details
University of Texas Southwestern Not yet recruiting Dallas Texas 75390 United States Details
Medical College of Wisconsin Not yet recruiting Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field